Beyond the Usual Suspects: RSV Infection in Patients With Hematological Malignancies Compared to Influenza and SARS‐COV‐2—A Report From the EPICOVIDEHA/EPIRESEHA Registry

hematological malignancy | neglected | opportunistic infection | real-world data | respiratory syncytial virusTo the Editor, Respiratory syncytial virus (RSV) is a major cause of acute respiratory infections and seasonal hospitalisations, particularly among immunocompromised adults [1].In patients with hematological malignancies, RSV can cause severe complications, including pneumonia, respiratory failure, and death, especially in those with lymphopenia, recent HSCT, or comorbidities [2].Although antivirals, monoclonal antibodies, and vaccines exist for other high-risk groups, their efficacy in this population remains uncertain [3].Screening and diagnostic protocols are inconsistent, treatments are often empiric, and hematological patients are largely excluded from clinical trials.Moreover, comparative data versus influenza and SARS-CoV-2 are limited, impeding the development of targeted, evidence-based prevention and management strategies for this vulnerable group [4].This study used the EPICOVIDEHA/EPIRESEHA registry [5] to describe RSV infection in adults with hematological malignancies Oliver A.